Dasatinib Combined With Chemotherapy in Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia

• Status: Active, not recruiting
• Trial end date: 2021-12-01

Summary

In this single-center, open-label, no control,prospective clinical trial, a total of 30 Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) patients will be enrolled. Dasatinib 100 mg per day will be given orally along with combination chemotherapy starting day 8 of induction chemotherapy. Dasatinib will be given continuously (if it's tolerable) for 2 years since achievement of complete remission (CR) as part of consolidation chemotherapy and maintenance therapy.Patients can receive allogeneic hematopoietic stem cell transplantation (HSCT) or autologous HSCT whenever possible during their first CR. Otherwise, they will finish the consolidation chemotherapy. The purpose of current study is to determine the clinical efficacy and tolerability of combination therapy of Dasatinib with multi-agent chemotherapy in newly-diagnosed Ph+ ALL.

• Phase: Phase 2

Details

• Lead Sponsor: Institute of Hematology & Blood Diseases Hospital
• Treatments: 6-Mercaptopurine; Cyclophosphamide; Cytarabine; Dasatinib; Daunorubicin; Dexamethasone; Etoposide; Mercaptopurine; Methotrexate; Mitoxantrone; Prednisone; Vincristine